Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
· ·
$32.13
▲ $0.15 (+0.5%)
Market data updated: 09/20 06:04 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
Not available
Day Range
$31.28 - $33.18
52-Week Range
$10.69 - $34.48
Beta
—
Next Earnings
04.11.2026
Support
$25.37
Resistance
$34.48
+68.1% (1Y)
Strengths: 11/28 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 27.5%
Growth
Biggest negative driver
Operating margin
Operating margin: -3.4% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
54
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
5d ago · $33.33
Evidence: Euphoria score crossed 55 (now 56)
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
46
Quality
63
Value
50
Momentum
64
Risk
40
Sentiment
100
Fundamental
25
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Oscar Health, Inc. has centered almost exclusively on its stock performance and investor sentiment, with no substantive updates on company operations or strategy. The headlines highlight OSCR surpassing key technical moving averages (20-day and 50-day), strong growth momentum (including a 272% earnings per share increase and high estimate revisions), and its inclusion on "Strong Buy" growth stock lists. Analysts note its small-cap status, which carries both potential upside and heightened risk. No operational or financial details beyond membership growth (46% to 2.96 million) are discussed.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Oscar Health, Inc.. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
46
🎯 Conviction (vs. Emotion)
42
Psychology
64
Fundamentals
25
Technical
64
Valuation
50
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+13%
Market Narrative
73
Fundamental Reality
42
Narrative Gap
+31
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
OSCR’s market behavior suggests a dominant overconfidence bias, where traders may overvalue momentum (+1.3% ROC) relative to weakening fundamentals (–17.9% EPS growth). The 24-point narrative gap (66 vs. 42) further implies a disconnect between market enthusiasm and underlying reality. Euphoria (44) and FOMO (23) reinforce this, as extreme sentiment (100/100) and elevated price (+29.3% above 200-day avg.) fuel speculative optimism. The key question: will traders remain detached from deteriorating fundamentals, or will reality intrude? Anchoring (4.9% from resistance) is negligible, suggesting no immediate price correction pressure.
Updated: 09/09/2026, 07:02 AM
What could change this?
👥 What the crowd believes
"Oscar Health, Inc. (OSCR) Just Overtook the 20-Day Moving Average"
"OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list"
"EPS up 272%, 86.6% estimate revisions, technical rating 8"
"Oscar Health's membership jumps 46% to 2.96 million, but seasonal enrollment and medical utilization keep profitability in focus"
🧠 Market Brain events driving this
📈 10D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Edgar Lawrence Smith — 69/100
🔴 Weakest match
Benjamin Graham (Enterprising Investor) — 7/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with the most bullish voices—Edgar Lawrence Smith and Philip Fisher—seeing it as a long-term hold or solid pick, scoring in the high 60s. Their optimism contrasts sharply with the overwhelming caution from defensive and contrarian investors: Benjamin Graham, Jack Schwager, and Howard Marks all flag it as risky or overvalued, scoring below 35. Meanwhile, market efficiency skeptics like Malkiel and Lynch see mixed potential, while cyclical analysts like Marks (Market Cycle) and Nelson warn of late-stage risks. The divergence stems from whether the stock’s fundamentals justify its valuation (Fisher/Smith) or if its price already reflects speculative fervor (Graham/Schwager), with volatility and liquidity concerns further polarizing the debate.
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 69
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 65
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 57
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 54
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 46
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 44
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 35
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 35
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 31
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 30
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 28
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 25
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 25
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 22
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 7
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (6 bullish · 3 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-3.4%
Net Margin
-3.8%
EBITDA Margin
-3.1%
ROE
-45.3%
ROA
-7.0%
ROIC
—
EPS
-$1.69
Cash
$2.77B
Total Debt
$430.10M
Current Ratio
0.95
Debt/Equity
0.44
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$3.73
Tangible Book Value per Share (Tangible NAV)
$3.73
Sentiment based on basic keywords (not AI) — 10 positive, 10 neutral, 0 negative out of the last 20 articles.
Yahoo · 20.9.2026
SeekingAlpha · 19.9.2026
Yahoo · 19.9.2026
Yahoo · 19.9.2026
Yahoo · 18.9.2026
Benzinga · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Benzinga · 17.9.2026
Benzinga · 17.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Benzinga · 17.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 16.9.2026
Benzinga · 16.9.2026
Yahoo · 16.9.2026
Oscar Health, Inc. (OSCR) currently has a StockIQ AI score of 54/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
OSCR currently scores 54/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
OSCR's technical score is 64/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 27.5%; Operating margin is stable or improving over time; Debt/equity: 0.44.
Based on the real signals StockIQ computed: Operating margin: -3.4% (negative); Net margin: -3.8% (negative); ATR: 5.8% of price.
StockIQ has no recorded dividend payment history for OSCR.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 9 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Baltrus Victoria | Open Market Sale | 3.9.2026 | 958 | -958 | $31.45 |
| Blackley Richard Scott | Open Market Sale | 3.9.2026 | 28,869 | -28,869 | $31.45 |
| McAnaney Adam | Open Market Sale | 3.9.2026 | 9,092 | -9,092 | $31.45 |
| Schlosser Mario | Open Market Sale | 3.9.2026 | 31,422 | -31,422 | $31.45 |
| Liang Janet | Open Market Sale | 3.9.2026 | 10,360 | -10,360 | $31.45 |
| Schlosser Mario | Open Market Sale | 28.8.2026 | 480,866 | -150,000 | $30.79 |
| Schlosser Mario | Conversion of Derivative Security | 28.8.2026 | 630,866 | +150,000 | — |
| Schlosser Mario | Exercise of Derivative Securities | 28.8.2026 | 2,990,000 | -150,000 | — |
| Schlosser Mario | Exercise of Derivative Securities | 28.8.2026 | 1,362,293 | +150,000 | $9.75 |
| Schlosser Mario | Conversion of Derivative Security | 28.8.2026 | 1,212,293 | -150,000 | — |
| Schlosser Mario | Conversion of Derivative Security | 28.8.2026 | 150,000 | +150,000 | — |
| Schlosser Mario | Exercise of Derivative Securities | 28.8.2026 | 150,000 | +150,000 | $9.75 |
| Schlosser Mario | Open Market Sale | 28.8.2026 | 150,000 | -150,000 | $30.79 |
| Schlosser Mario | Conversion of Derivative Security | 28.8.2026 | 150,000 | -150,000 | — |
| Schlosser Mario | Exercise of Derivative Securities | 28.8.2026 | 150,000 | -150,000 | — |
| Schlosser Mario | Exercise of Derivative Securities | 27.8.2026 | 1,812,293 | +600,000 | $9.75 |
| Schlosser Mario | Conversion of Derivative Security | 27.8.2026 | 1,212,293 | -600,000 | — |
| Schlosser Mario | Exercise of Derivative Securities | 27.8.2026 | 3,140,000 | -600,000 | — |
| Schlosser Mario | Open Market Sale | 27.8.2026 | 480,866 | -600,000 | $30.34 |
| Schlosser Mario | Conversion of Derivative Security | 27.8.2026 | 1,080,866 | +600,000 | — |
| Schlosser Mario | Open Market Sale | 27.8.2026 | 600,000 | -600,000 | $30.34 |
| Schlosser Mario | Conversion of Derivative Security | 27.8.2026 | 600,000 | +600,000 | — |
| Schlosser Mario | Exercise of Derivative Securities | 27.8.2026 | 600,000 | -600,000 | — |
| Schlosser Mario | Conversion of Derivative Security | 27.8.2026 | 600,000 | -600,000 | — |
| Schlosser Mario | Exercise of Derivative Securities | 27.8.2026 | 600,000 | +600,000 | $9.75 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
16,364,378 shares short as of 2026-08-31 · vs. 17,825,961 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
44.1% of trading volume this week was short selling, vs. 38.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology